59th Annual Meeting of the Japanese Society of Neurology

Presentation information

Print

Hot Topics

[HT-02] Nucleic acid therapeutics

Wed. May 23, 2018 1:20 PM - 3:10 PM Room 9 (Royton Sapporo / Regent Hall （2F）)

Chair: Takanori Yokota(Department of Neurology and Neurological Science,Tokyo Medical and Dental University, Japan), Yoshitsugu Aoki(Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Japan)

Nucleic Acids Therapeutics Society of Japan

[HT-02-4] A first Antisense Oligonucleotide (ASO) therapy, Nusinersen, for Spinal Muscular Atrophy

○Shinichi Torii (Biogen Japan Ltd., Japan)

March, 1984 Graduated from Gifu College of Pharmacy
March, 2002 Ph.D degree from Molecular Biology from Tokyo University, Graduate School

April, 1984～ Janssen Pharmaceutical K.K.
April, 2007～ Celgene Corporation
April, 2010～ Olympus Corporation
January, 2011～ Chief Scientific Officer (CSO), Olympus Biotech Corporation (Boston, USA)
June, 2014～ Head of R&D, Biogen Japan Inc.
April, 2017～ President & Representative Director, Biogen Japan Inc.

Abstract password authentication.
Password is written on a pocket program and name badge.

Password